<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03807973</url>
  </required_header>
  <id_info>
    <org_study_id>R18-179</org_study_id>
    <nct_id>NCT03807973</nct_id>
  </id_info>
  <brief_title>Tracking Peripheral Immune Cell Infiltration of the Brain in Central Inflammatory Disorders Using [Zr-89]Oxinate-4-labeled Leukocytes.</brief_title>
  <official_title>Tracking Peripheral Immune Cell Infiltration of the Brain in Central Inflammatory Disorders Using [Zr-89]Oxinate-4-labeled Leukocytes.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will use brain PET/MRI and an investigational radioactive drug called [Zr-89]oxine&#xD;
      to track the location of white blood cells (also called leukocytes) in the body. PET/MRI will&#xD;
      be used to visualize labeled white blood cells and determine if they enter the central&#xD;
      nervous system in conditions associated with brain inflammation (also called&#xD;
      neuroinflammation). By better understanding the roleneuroinflammation in fibromyalgia,&#xD;
      chronic fatigue syndrome, and multiple sclerosis, the investigator hopes to be able to better&#xD;
      diagnose and treat patients in the future.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 30, 2021</start_date>
  <completion_date type="Anticipated">April 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Regional brain distribution of radiolabeled white blood cells</measure>
    <time_frame>3 years</time_frame>
    <description>Descriptive statistics (means and standard deviations) of standardized uptake values (SUVs) will be presented for the patient groups and healthy controls in the following regions: whole brain, gray matter, white matter, atlas-based regions of interest, and lesions (MS patients only). Normality of the SUV distribution will be tested using Shapiro-Wilk tests, and the data will be transformed to normal distribution if necessary.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Fibromyalgia</condition>
  <condition>Chronic Fatigue Syndrome</condition>
  <condition>Multiple Sclerosis</condition>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Fibromyalgia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Chronic Fatigue Syndrome</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple Sclerosis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Controls</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[Zr-89]Oxine-labeled leukocytes PET/MR</intervention_name>
    <description>All study participants will undergo an investigational imaging study using autologous [Zr-89]-lableled leukocytes and brain PET/MRI. Participants will undergo a venous blood draw, and the leukocutes in the blood sample will be isolated for labeling using [Zr-89]oxine. The labeled leukocutes (7.4- 18.5 MBq, 200-500 uCi) will be re-injected into the participant followed by brain PET/MRI at 24-48 hours after injection. Participants will be asked to have a second brain imaging study 3-6 days after this injection, but this second imaging study is optional.</description>
    <arm_group_label>Chronic Fatigue Syndrome</arm_group_label>
    <arm_group_label>Fibromyalgia</arm_group_label>
    <arm_group_label>Healthy Controls</arm_group_label>
    <arm_group_label>Multiple Sclerosis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        1.18 to 65 years of age 2.Healthy volunteer OR&#xD;
&#xD;
          -  Clinical diagnosis of Multiple Sclerosis (MS) OR&#xD;
&#xD;
          -  Meets 2016 American College of Rheumatology (ACR) case definition criteria for&#xD;
             fibromyalgia OR&#xD;
&#xD;
          -  Meets 1994 Fukuda case definition criteria for Chronic Fatigue Syndrome&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Contraindication to MRI&#xD;
&#xD;
          2. Pregnancy&#xD;
&#xD;
          3. Lactation&#xD;
&#xD;
          4. Individuals who are unable to participate in the imaging portion due to severity of&#xD;
             their medical condition&#xD;
&#xD;
          5. Chronic infectious disease (e.g. HIV, HCV)&#xD;
&#xD;
          6. Viral or bacterial illness requiring medical attention and/or antibiotics within 1&#xD;
             month of study participation&#xD;
&#xD;
          7. Diagnosis of cancer, including leukemia&#xD;
&#xD;
          8. Blood or blood clotting disorder&#xD;
&#xD;
          9. Except for individuals with MS, a diagnosis of autoimmune disease is exclusionary&#xD;
&#xD;
         10. Positive urine Î²-hCG test day of procedure or a serum hCG test within 48 hours prior&#xD;
             to the administration of [89Zr]Oxinate-4-labeled leukocytes&#xD;
&#xD;
         11. Currently enrolled in a clinical trial utilizing experimental therapies&#xD;
&#xD;
         12. Contraindication to gadolinium based contrast agents&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jonathan McConathy, MD, PhD</last_name>
    <phone>205-996-7115</phone>
    <email>jmcconathy@uabmc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>April Riddle, BSRT</last_name>
    <phone>205-934-6504</phone>
    <email>ariddle@uabmc.edu</email>
  </overall_contact_backup>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 14, 2019</study_first_submitted>
  <study_first_submitted_qc>January 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 17, 2019</study_first_posted>
  <last_update_submitted>January 15, 2021</last_update_submitted>
  <last_update_submitted_qc>January 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alabama at Birmingham</investigator_affiliation>
    <investigator_full_name>Jonathan E McConathy</investigator_full_name>
    <investigator_title>MD, PhD, Director for the Division Molecular Imaging and Therapeutics</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatigue Syndrome, Chronic</mesh_term>
    <mesh_term>Fibromyalgia</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

